Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2011

View Archived Issues

Novel kinase inhibitors identified at Abraxis BioScience

Celtic Therapeutics acquires RX-10045 from Resolvyx Pharma

Gruenenthal claims new bradykinin B1 receptor antagonists

InSite Vision files IND for ISV-101 for dry eye disease

Merck & Co. confirms changes to two phase III trials of vorapaxar

Effects of eritoran tetrasodium in sepsis evaluated by phase II data analyses

CVA21 and doxorubicin demonstrate synergistic anticancer activity in vivo

Self-assembling KGF-ELP nanoparticles show promise in wound healing

Vicept Therapeutics reports phase II data on V-101 in rosacea

OncoMed begins phase I trial of OMP-59R5 in advanced solid tumors

Biotie Therapies presents new integrin alpha-2/beta-1 inhibitors

Chimeric SARS S/influenza M1 VLPs protect mice from SARS

Lupin divulges new dipeptidyl peptidase 4 inhibitors

FibroGen commences phase II trial of FG-3019 in IPF

Threshold Pharma claims new camptothecin derivatives for cancer therapy

FDA limits amount of acetaminophen in prescription combination products

Shionogi launches Kapvay in U.S. for ADHD

Dyax and Sigma-Tau expand agreement to commercialize Kalbitor

SCV-07 advances in phase IIb trial for prevention of oral mucositis in head and neck cancer

University of Edinburgh divulges new 11-beta-HSD1 inhibitors

Excaliard reports data from three phase II trials of EXC-001

ChemGenex notifies EMA of withdrawal of MAA for Tekinex for Ph+ CML

Dynavax completes enrollment in phase III Heplisav trial

Oryzon receives grant to support research of lysine-specific histone demethylase 1A

FDA extends PDUFA date for Gestiva

MedImmune begins phase I MEDI-565 trial in gastrointestinal cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...